Baseline characteristics of the patients
| Characteristic . | Rivaroxaban (n = 59) . | Warfarin (n = 61) . |
|---|---|---|
| Females, n (%) | 39 (66) | 38 (62) |
| Age, y | 46.5 ± 10.2* | 46.1 ± 13.2* |
| Body mass index, kg/m2 | 26.1 ± 6.1* | 25.5 ± 5.9* |
| CrCl, mL/min | 117.0 ± 38.6* | 109.3 ± 36.7* |
| Hemoglobin, g/L | 131.7 ± 17.6* | 135.9 ± 17.1* |
| Platelet count, ×109/L | 214.9 ± 73.8* | 209.3 ± 63.5* |
| APS laboratory test positivity, n | ||
| LA: dRVVT/aPTT/both | 16/5/38 | 14/7/40 |
| aCL: IgG or IgG + IgM/IgM only | 57/2 | 52/9 |
| aβ2GPI: IgG or IgG + IgM/IgM only | 57/2 | 52/9 |
| Autoimmune disease, n (%) | 24 (41) | 25 (41) |
| Systemic lupus erythematosus | 10 | 15 |
| Other autoimmune disease | 14 | 10 |
| Previous thrombotic events, n (%) | ||
| Arterial events | 11 (19) | 14 (23) |
| Stroke | 8 | 8 |
| Acute myocardial infarction | 0 | 2 |
| Other sites | 3 | 4 |
| Venous events | 38 (64) | 39 (64) |
| Deep vein thrombosis and/or pulmonary embolism | 36 | 32 |
| Other sites | 2 | 7 |
| Venous and arterial events | 10 (17) | 8 (13) |
| Pregnancy morbidity, n (%)† | 16 (41) | 12 (32) |
| Risk factors, n (%) | ||
| Smoking‡ | 31 (53) | 29 (48) |
| Hypertension | 15 (25) | 22 (36) |
| Diabetes | 4 (7) | 0 (0) |
| Dyslipidemia | 12 (20) | 15 (25) |
| Other hypercoagulable condition | 9 (15) | 9 (15) |
| Medications at time of randomization, n (%) | ||
| Hydroxychloroquine | 15 (25) | 23 (38) |
| Corticosteroids | 11 (19) | 13 (21) |
| Other immunosuppressive drugs | 17 (29) | 21 (34) |
| Aspirin | 11 (19) | 10 (16) |
| Statins | 7 (12) | 10 (16) |
| Characteristic . | Rivaroxaban (n = 59) . | Warfarin (n = 61) . |
|---|---|---|
| Females, n (%) | 39 (66) | 38 (62) |
| Age, y | 46.5 ± 10.2* | 46.1 ± 13.2* |
| Body mass index, kg/m2 | 26.1 ± 6.1* | 25.5 ± 5.9* |
| CrCl, mL/min | 117.0 ± 38.6* | 109.3 ± 36.7* |
| Hemoglobin, g/L | 131.7 ± 17.6* | 135.9 ± 17.1* |
| Platelet count, ×109/L | 214.9 ± 73.8* | 209.3 ± 63.5* |
| APS laboratory test positivity, n | ||
| LA: dRVVT/aPTT/both | 16/5/38 | 14/7/40 |
| aCL: IgG or IgG + IgM/IgM only | 57/2 | 52/9 |
| aβ2GPI: IgG or IgG + IgM/IgM only | 57/2 | 52/9 |
| Autoimmune disease, n (%) | 24 (41) | 25 (41) |
| Systemic lupus erythematosus | 10 | 15 |
| Other autoimmune disease | 14 | 10 |
| Previous thrombotic events, n (%) | ||
| Arterial events | 11 (19) | 14 (23) |
| Stroke | 8 | 8 |
| Acute myocardial infarction | 0 | 2 |
| Other sites | 3 | 4 |
| Venous events | 38 (64) | 39 (64) |
| Deep vein thrombosis and/or pulmonary embolism | 36 | 32 |
| Other sites | 2 | 7 |
| Venous and arterial events | 10 (17) | 8 (13) |
| Pregnancy morbidity, n (%)† | 16 (41) | 12 (32) |
| Risk factors, n (%) | ||
| Smoking‡ | 31 (53) | 29 (48) |
| Hypertension | 15 (25) | 22 (36) |
| Diabetes | 4 (7) | 0 (0) |
| Dyslipidemia | 12 (20) | 15 (25) |
| Other hypercoagulable condition | 9 (15) | 9 (15) |
| Medications at time of randomization, n (%) | ||
| Hydroxychloroquine | 15 (25) | 23 (38) |
| Corticosteroids | 11 (19) | 13 (21) |
| Other immunosuppressive drugs | 17 (29) | 21 (34) |
| Aspirin | 11 (19) | 10 (16) |
| Statins | 7 (12) | 10 (16) |